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Abstract
Background: Multiple sclerosis (MS) is a stressful condition. Mental health comorbidity is common. Stress can increase
the risk of depression, reduce quality of life (QOL), and possibly exacerbate disease activity in MS. Mindfulness-Based Stress
Reduction (MBSR) may help, but has been little studied in MS, particularly among more disabled individuals.
Methods: The objective of this study was to test the feasibility and likely effectiveness of a standard MBSR course for
people with MS. Participant eligibility included: age > 18, any type of MS, an Expanded Disability Status Scale (EDSS)
</= 7.0. Participants received either MBSR or wait-list control. Outcome measures were collected at baseline,
post-intervention, and three-months later. Primary outcomes were perceived stress and QOL. Secondary
outcomes were common MS symptoms, mindfulness, and self-compassion.
Results: Fifty participants were recruited and randomised (25 per group). Trial retention and outcome
measure completion rates were 90% at post-intervention, and 88% at 3 months. Sixty percent of participants
completed the course. Immediately post-MBSR, perceived stress improved with a large effect size (ES 0.93;
p < 0.01), compared to very small beneficial effects on QOL (ES 0.17; p = 0.48). Depression (ES 1.35; p < 0.05),
positive affect (ES 0.87; p = 0.13), anxiety (ES 0.85; p = 0.05), and self-compassion (ES 0.80; p < 0.01) also
improved with large effect sizes. At three-months post-MBSR (study endpoint) improvements in perceived
stress were diminished to a small effect size (ES 0.26; p = 0.39), were negligible for QOL (ES 0.08; p = 0.71),
but were large for mindfulness (ES 1.13; p < 0.001), positive affect (ES 0.90; p = 0.54), self-compassion (ES 0.83;
p < 0.05), anxiety (ES 0.82; p = 0.15), and prospective memory (ES 0.81; p < 0.05).
Conclusions: Recruitment, retention, and data collection demonstrate that a RCT of MBSR is feasible for people with
MS. Trends towards improved outcomes suggest that a larger definitive RCT may be warranted. However, optimisation
changes may be required to render more stable the beneficial treatment effects on stress and depression.
Trial registration: ClinicalTrials.gov Identifier NCT02136485; trial registered 1st May 2014.
Background
Multiple sclerosis (MS) is a stressful condition, with un-
predictable relapses and disease progression [1], prob-
lematic comorbidity [2], complex drug regimens [3], and
manifold social and role difficulties [1]. Stress may con-
tribute to disease activity in MS [4, 5], is burdensome,
can negate health-promoting behaviors [6], may contrib-
ute to the development of anxiety and depression and
impair quality of life (QOL) in MS [7, 8]. Anxiety and
depression are common in MS [2]. Evidence to support
the use of pharmacological treatments for mental health
comorbidities in MS is limited, with problematic side ef-
fects noted [9]. Amongst psychological interventions,
cognitive behavioural therapy (CBT) approaches are
often used, but evidence is limited and reviews consist-
ently highlight a need for further high quality research
to identify other effective and acceptable interventions
[10]. CBT has the strongest evidence for treating depres-
sion [10] and stress [11] in MS, but effective treatments
for anxiety are lacking [10].
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Mindfulness-based interventions (MBIs) are increas-
ingly used to manage mental health problems and
stress in long-term conditions (LTCs), with meta-
analytic studies reporting comparable efficacy to both
CBT and antidepressants [12]. MBIs are multicom-
ponent complex interventions that teach a variety of
meditation skills to facilitate the development of
‘mindfulness’ [13]. The term mindfulness is often
defined as; ‘paying attention in a particular way: on
purpose, in the present moment, and non-judgmentally’
[14]. How MBIs work is not fully understood, but
improved executive skills and enhanced emotion
regulation are thought key mechanisms [15, 16].
Mindfulness-Based Stress Reduction (MBSR) was the
original model for MBIs, first used for people with
chronic pain [17]. MBIs have since been applied to a
wide range of other LTCs, with existing evidence sup-
porting their use in anxiety [18], recurrent depression
[18], and somatisation [19].
In people with MS, a recent systematic review
found limited evidence that MBIs may improve anx-
iety, depression, pain, fatigue, balance, and QOL [20].
Since then, further evidence suggests potential cost-
effectiveness [21]. However, how best MBIs should be
delivered to diverse MS populations remains unclear.
Differing demographic factors such as age, sex, socio-
economic status (SES), ethnicity, comorbidity, and
greater levels of disability could conceivably impact
on effectiveness. Prior studies have largely focused on
distinct disease phenotypes [21, 22], or less disabled
individuals [23–27], meaning that previous findings
suggesting benefit from MBSR [24] may not apply to
the wider spectrum of people with MS. Only one
prior study has reported detailed feasibility findings
for the use of MBIs in people with MS, where data is
limited to people with progressive disease [21]. Very
little is thus known about the feasibility, acceptability,
accessibility, and implementability of standard MBSR
for people with MS.
The aim of the study described in this paper was to
determine the feasibility of conducting a definitive
phase-3 randomised controlled trial (RCT) of stand-
ard MBSR and to obtain initial estimates of likely
effectiveness.
Methods
Trial design and participants
This was a phase-2 exploratory RCT to assess the feasibil-
ity (engagement and retention), and likely effectiveness of
MBSR in people with MS. It was conducted in Glasgow,
Scotland, United Kingdom (UK). Acceptability, accessibil-
ity, and implementability were also assessed via nested
qualitative semi-structured interviews (recently submitted
for publication) and will be reported elsewhere.
The study employed a wait-list control design,
meaning that all study participants eventually received
MBSR. We aimed to recruit 50 adults with MS within
3 months. Between June and August 2014, partici-
pants were recruited from National Health Service
(NHS) sites in Greater Glasgow. Participants were
recruited directly by clinical staff on NHS sites pro-
viding MS services; by alerting all GPs in this health
board area by email; advertising via NHS/third-sector
bodies (MS Revive); through internet adverts (MS
Society UK), and the University of Glasgow Twitter/
Facebook social media outlets. Full inclusion and
exclusion criteria are provided below (Table 1).
A priori stopping criteria were for trial discontinuation
in the occurrence of any adverse event(s) strongly sug-
gesting harm from the intervention.
Recruited participants had baseline measures and
informed consent collected face-to-face, prior to ran-
domisation. All measures were self-completed; firstly
with a researcher present, then on subsequent itera-
tions by the participant alone. Follow-up measures
were collected by post, at intervention completion (2
months), and then again 3 months later (at 5
months). Those who did not return postal measures
within 14 days were telephoned to confirm ongoing
participation. After waiting 2 weeks for response, the
average number of reminder calls required was 4.4.
Participants received a £5 gift voucher as a gesture of
appreciation for completing each questionnaire.
Randomisation and blinding
An independent, blinded statistician from the Robertson
Centre for Biostatistics (RCB) at the University of Glas-
gow undertook randomisation and sequence generation,
once all baseline measures had been collected. Block
sizes of two were generated, to prevent over-allocation
to either group. Blinded staff at the University of Glas-
gow with no prior knowledge of participants handled
treatment allocation. Questionnaire data was identifiable
Table 1 Study eligibility criteria
Inclusion 1) Over 18 years of age;
2) Neurologist confirmed diagnosis of MS
(Poser or McDonald criteria depending on year of diagnosis);
3) Able to understand spoken and written English;
4) A score of less than or equal to 7.0 on the
Expanded Disability Status Scale (EDSS) [49]
Exclusion 1) Life-threatening physical or mental health
comorbidities (i.e. suicidal ideation, active
psychosis, or terminal/life threatening inter-current
medical illness), or such conditions expected to
significantly limit participation and adherence
(eg dementia, pregnancy, on going substance abuse);
2) Those currently receiving another form of
psychological intervention (non-pharmacological).
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only by a random study number, and data entry for
all outcome measures was done by a researcher
blinded to group allocation. It was impossible to blind
participants or MBSR instructors to their treatment
allocation.
Patient involvement
The trial protocol was prospectively reviewed by
three patient members of the UK MS Society re-
search network who provided favourable feedback
for the study.
Intervention
The intervention was based on standard MBSR, includ-
ing home practice materials, but without the day retreat
at week six; excluded for pragmatic, space-constraint
reasons, as well as empirical evidence contesting its ne-
cessity [28] (Additional file 1). All MBSR classes were
led by two experienced physician facilitators and took
place at the NHS Centre for Integrative Care (NHS
CIC), in Glasgow.
MBSR instructors
The MBSR instructors were used to working together.
Over the previous 3 years they had regularly taught
weekly mindfulness groups to multimorbid people with
a variety of LTCs (including MS) as part of their routine
clinical responsibilities. However, neither instructor had
taught groups exclusively for people with MS.
The first MBSR instructor had a clinical background
in General Practice since 1983 and worked full time as a
Specialty Doctor at the NHS CIC. She had completed
teacher training in Mindfulness-Based Cognitive Ther-
apy (MBCT) in 2005, via the University of Bangor, and
had been teaching mindfulness regularly since then. She
had also completed residential MBSR training in with
Jon-Kabat-Zinn, in the USA in 2011, and regularly
attended training retreats in MBCT and Vipasana medi-
tation. She had a teaching qualification in Pranayama
and Iyengar Yoga. She regularly attended one-to-one
mindfulness clinical supervision and had a longstanding
daily practice.
The second MBSR instructor also came from a Gen-
eral Practice background, completing her clinical train-
ing in 1994. She qualified as a mindfulness teacher in
2011 via the University of Bangor. She was halfway
through completing an MSc in teaching mindfulness via
the University of Bangor and had a longstanding daily
mindfulness practice with regular clinical supervision.
Intervention fidelity
Fidelity assessment was informed by the National Insti-
tutes of Health guidance for behavioural interventions
[29] (Table 2).
However, the UK Medical Research Council (MRC)
guidance for developing and evaluating complex inter-
ventions [13] suggests that any such measures should
be flexible during the early stages of evaluation of a
novel intervention/context. For example, there was no
‘reviewer’ sitting in or video-recording the classes,
something that would be important in a full-scale
trial.
Outcome objectives
As a feasibility study, the main outcome objectives were:
1. To determine if recruitment, delivery, and retention
for a RCT of MBSR was feasible
2. To determine if outcome measurement data
collection was feasible
3. To assess likely effectiveness on outcome measures
in a definitive trial
The primary participant-report outcomes were:
a. Perceived stress (Perceived Stress Scale-10 – PSS
[30])
b. Quality of life (EQ-5D-5 L) [31].
Table 2 Treatment fidelity
Domain of fidelity How it was met
1. Study design A priori study protocol; fixed number/length of
MBSR sessions; recording of any protocol
deviations; scripted manual for course; external
monitoring by research team and MBSR
instructor not part of the research project;
monitoring homework completion
2. Provider training Qualified and experienced mindfulness
teachers trained together using standardised
MBSR treatment manuals; same instructors
throughout; regular external provider
debriefing and supervision; easy access to
senior research staff (SM); participant exit




Qualitative assessment of provider ‘warmth/
credibility’ from participants, complaint
monitoring; treatment workbook provided to
all participants;
4. Improving receipt of
MBSR
Providers asked for weekly participant feedback,
both verbal, and in writing (embedded
questionnaire – not part of study data);
completion of regular activity logs; participant
and provider feedback on MBSR exercises




Semi-structured participant interviews on
completion; regular home practice and
materials provided along with diary for
adherence; in class discussion/post-interview
discussion on ongoing use/application of MBSR
skills in daily life
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Secondary participant-report outcomes sought to:
1. Capture common MS symptoms with a MS specific
measure (Multiple Sclerosis Quality of Life
Inventory - MSQLI) [32]. The MSQLI includes
measures of:
a. Fatigue (cognitive, physical, psychosocial)
(Modified Fatigue Impact Scale – MFIS)
b. Mental health (anxiety, depression, behavioural
control, positive affect) (Mental Health
Inventory-18 - MHI)
c. Social support (tangible, emotional, affection,
positive interactions) (Modified Social Support
Survey - MSSS)
d. Cognitive function (attention, retrospective
memory, prospective memory, planning)
(Perceived Deficits Questionnaire - PDQ)
e. Pain (Pain Effects Scale – PES)
f. Visual function (Impact of Visual Impairment
Scale - IVIS)
g. Bladder function (Bladder Control Scale - BCS)
h. Bowel function (Bowel Control Scale - BWCS)
i. Sexual satisfaction (Sexual Satisfaction Scale – SSS)
2. Assess items measuring the putative processes of
mindfulness:
a. Mindfulness (Mindful Attention Awareness Scale
– MAAS) [33].
b. Self-compassion (Self-Compassion Scale - short
form – SCS-sf ) [34].
3. Measure emotional lability via the Emotional Lability
Questionnaire (ELQ) [35].
For psychometric properties and justification of mea-
sures used, see Additional file 2.
A baseline participant questionnaire also recorded
demographic information, including deprivation, as
measured by the Scottish Index of Multiple
Deprivation (SIMD) [36], number of comorbid condi-
tions, and use of disease-modifying, antidepressant, or
analgesic medications.
Statistical analysis
An a priori statistical analysis plan was developed in
conjunction with a Consultant Biostatistician from the
Robertson Centre for Biostatistics, University of Glasgow.




Key outcomes to assess feasibility, acceptability, and
accessibility included rates of recruitment and retention.
These were recorded using descriptive statistics.
Baseline characteristics were summarised by interven-
tion arm.
Differences were tested via two-sample t-tests for nor-
mally distributed variables, and chi-squared tests for cat-
egorical variables. Questionnaire outcome data were
analysed relative to change from baseline via an analysis
of covariance (ANCOVA) approach, where adjustments
were made for the baseline score, as appropriate, includ-
ing age, sex, and deprivation, as well as any other char-
acteristics found to differ between the intervention arms
at baseline. On the advice of the statistician, age, sex,
and SES were included as common confounders, how-
ever, unadjusted analyses were also undertaken for
comparison.
An a priori decision was made not to perform data im-
putation for missing values. There were no interim ana-
lyses performed. All statistical analyses were undertaken
using SPSS v21.
For questionnaire data, results are reported for be-
tween group mean (standard deviation - SD) baseline
scores, change scores, treatment effects (β) with 95%
confidence intervals (95% CIs), significance levels, and
effect sizes (ES) (Cohen’s ‘d’) with 95% CIs.
Sample size calculation
Given the aim of this study being to assess feasibility
and power estimate for a phase-3 trial, sample size was
not based on a power calculation. However, based on
the advice of a statistician, a working sample size of 50
people was chosen as:
1. Browne [37] has demonstrated that an ‘n’ of 30 is
sufficient to allow estimates of sample size for an
efficacy trial.
2. Pragmatic reasons including a) the MBSR
instructors were used to routinely delivering groups
of this size; and b) space constraints meant that a
maximum of 25 participants could be
accommodated in each group.
Data access
Data for the trial was accessible to all authors (RS, FM,
SM), who each contributed to its interpretation.
Results
Objective 1 - To determine if recruitment, delivery, and
retention for a large scale RCT of MBSR were feasible
In total, 101 patients were approached, of whom 66
(65%) contacted the researcher (RS) and were screened.
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Following screening, three people were ineligible
(EDSS > 7.0), and 13 declined to take part due to: diffi-
culties securing transport (n = 7); difficulty getting time
off work (n = 4); thought the course would be too tiring
(n = 1); unclear (n = 1). Consent rate was thus 50/66, or
76%. Recruitment was completed within 10 weeks (out
of the pre-specified 12) (Table 3).
Following randomisation, one participant assigned to
MBSR could not attend the allocated dates, and thus did
not receive the intervention, but continued to complete
measures throughout, and another three participants
withdrew due to: a) a MS symptom exacerbation (fa-
tigue), b) family conflict, and c) becoming enrolled in a
pharmacological trial. Thus, from the 25 participants
originally assigned to the intervention, only 21 could at-
tend any classes. See Fig. 1 below for a detailed CON-
SORT flow diagram.
Treatment adherence
Treatment adherence was assessed via attendance at the
MBSR sessions, and via home practice recordings. Fifteen
participants (60%) attended four or more MBSR sessions,
meeting the criteria for course ‘completion’. There were
no significant differences in demographic factors between
completers and non-completers (Additional file 3).
Reasons cited for session non-attendance included
inter-current illness, work commitments, being on
holiday, and ‘sleeping-in’. See Table 4 for details of
MBSR session attendance.
Participants were asked to return a home-practice log
each week, but only 16/25 (60%) people returned any
data. From these, an average home practice time of
32.5 min per day was observed. Four people allocated to
MBSR did not attend any sessions, and provided no data
on home-practice.
Baseline participant characteristics
The sample at baseline had a mean age (SD) of 44.96
(10.90), was predominantly female (92%), and of White
Scottish ethnicity (98%). Forty participants (80%) had
Relapsing Remitting MS (RRMS), eight (16%) had Sec-
ondary Progressive (SPMS), and two (4%) had Primary
Progressive disease (PPMS). The mean (SD) EDDS was
4.41 (1.75). After randomisation, the intervention and
control groups were similar in terms of age, sex, SES,
ethnicity, level of education, MS phenotype, disease dur-
ation, number of comorbidities, and EDSS score, with
the only significant baseline difference relating to previ-
ous meditation/yoga experience, which by chance was
higher in the intervention group. Thus, this potential
confounder was controlled for in the subsequent ana-
lyses, along with age, sex, and SES. Baseline demo-
graphic and clinical data are summarised in Table 5.
Objective 2 - To determine if outcome measurement data
collection was feasible
All 50 participants completed outcome measures at
baseline (100%). At the post intervention point (two-
months) 45/50 (90%) returned these measures, and at
the final follow-up point (five-months) 44/50 (88%) were
returned. Over the entire period for collecting post-
intervention and follow-up measures, an average of 4.4
telephone reminders were required per participant (222
calls in total). Missing data varied considerably across the
range of outcome measures. Thirty-nine out of 50 (78%)
participants returned at least one item of missing data,
and it was commoner among measures towards the back
of the questionnaire. It was lowest on the EQ-5D-5 L (0–
12%), and highest for the SCS-sf (2–22%), with 13/15
measures having less than 20% missing values. There were
no significant differences in age (Mean age 47.12 [SD
10.44] vs. 44.96 [SD 10.90]; p = 0.39), disability level
(Mean EDSS 4.51 [SD 1.77] vs. 4.41 [SD 1.75]; p = 0.40),
or SES (Mean deprivation decile 5.08 [SD 2.64] vs. 5.22
[SD 2.71]; p = 0.60) between those returning missing
values, and those who did not. See Additional file 4 for
further details regarding missing data.
Table 3 Sources of trial recruitment and relative contributions
Source of engagement/
recruitment








MS Specialist Nurses 75 52 34 68%
MS Revive Nurse 6 6 6 12%
Integrative Medicine Specialists 9 9 5 10%
General practitioners 11 11 5 10%
Via MS Society advertisement Freely available online 2 0 0%
Via University web (Twitter/ Facebook) Freely available online 0 0 0%
Via protocol (clinical trials.gov) Freely available online 5 0 0%
Total 101(+) 85 50 N/A
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Objective 3 - To assess likely effectiveness on outcome
measures in a definitive trial
There were no significant differences between the
groups on any of the baseline outcome measures. Two
models were explored in the analyses 1) a ‘raw’ model
that made no adjustments for demographic factors; and 2)
a model that adjusted for age, sex, SES, and previous
yoga/meditation experience. There were only minor differ-
ences between the models. In the raw model beneficial
effect sizes were slightly larger on all measures (Additional
file 5). As such, the model presented below is that adjusted
for age, sex, deprivation and previous yoga/meditation
experience.
In the model adjusted for age, sex, SES, and previ-
ous meditation/yoga experience, at immediately post-
MBSR, PSS scores improved with a large effect size
(ES 0.93; p < 0.05), but EQ-5D-5 L scores showed
only very small improvement (ES 0.17; p = 0.48).
From the secondary outcomes, improvements with a
large effect size were evident for depression (ES 1.35;
p < 0.05), positive affect (ES 0.87; p = 0.13), anxiety
(ES 0.85; p = 0.05), and self-compassion (ES 0.80;
p < 0.01). Overall, 14 out of 15 of the composite out-
come measures (primary and secondary) showed a
positive trend for treatment effect immediately post-
MBSR (Fig. 2).
Fig. 1 CONSORT flow diagram
Table 4 MBSR session attendance
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At follow-up, 3 months following MBSR, beneficial ef-
fects on the PSS had diminished to a small effect size (ES
0.26; p = 0.39) and those for the EQ-5D-5 L were negligible
(0.08; p = 0.71). From secondary outcomes, improvements
with a large effect size were evident for mindfulness (ES
1.21; p < 0.001), positive affect (ES 0.90; p = 0.54), anxiety
(ES 0.82; p = 0.15), prospective memory (ES 0.81; p < 0.05),
and self-compassion (ES 0.80; p < 0.05). There was an
overall trend towards improvement on 14 out of 15 of the
composite measures (Fig. 3).
See Figs. 2 and 3 for a graphical summary of treatment ef-
fects for adjusted models covering the PSS, EQ-5D-5 L, the
MSQLI, MAAS, SCS-sf, and the ELQ. Further statistical de-
tails are outlined in Tables AF6.1–AF6.9 in Additional file 6.
Harms
One participant allocated to the intervention group re-
ported an exacerbation in her symptoms of neuropathic
pain following her first and only MBSR class.
Discussion
This study assessed the feasibility of delivering MBSR
for people with MS in an exploratory phase-2 RCT. We
recruited our target of 50 participants within 3 months.
Table 5 Baseline participant characteristics
Intervention Control Significance p
Mean age in years
(standard deviation - SD)
43.6 (10.7) 46.3 (11.1) 0.37
Sex Female 23 (92%) Female 22 (88%) 1.00
Ethnicity White British 25 (100%) White British 25 (100%) 1.00
MS phenotype
RRMS – relapsing remitting;
SPMS – secondary progressive;
PPMS – primary progressive
RRMS 22 (88%) RRMS 18 (72%) 0.74
SPMS 1 (4%) SPMS 7 (28%)
PPMS 2 (8%)
Deprivation 5.0 (2.8) 5.4 (2.6) 0.64
Education – highest level Secondary school 3 (12%) Secondary school 5 (20%) 0.73
College 7 (28%) College 7 (28%)
University 15 (60%) University 13 (52%)
Employment Full time 4 (16%) Full time 7 (28%) 0.39
Part time 3 (12%) Part time 6 (24%)
Unemployed 6 (24%) Unemployed 7 (28%)
Retired 5 (20%) Retired 3 (12%)
Other 7 (28%) Other 2 (8%)
Living arrangement Lives alone 6 (24%) Lives alone 3 (12%) 0.54
With partner 9 (36%) With partner 10 (40%)
With family/friends 10 (40%) With family/friends 12 (48%)
EDSS 4.5 (1.8) 4.3 (1.7) 0.64
Mean disease duration
in years (SD)
8.9 (8.5) 9.6 (9.4) 0.79
Mean total comorbidity
count (SD)
2.5 (2.2) 2.3 (1.9) 0.68
Mean mental health
comorbidity count (SD)
0.8 (0.83) 0.7 (0.8) 0.73
• Comorbid anxiety 11 (44%) 8 (32%) 0.12
• Comorbid depression 9 (36%) 11 (44%) 0.29
Mean physical health
comorbidity count (SD)
1.8 (1.5) 1.6 (1.5) 0.71
Using analgesic drugs 19 (76%) 17 (68%) 0.75
Using disease modifying drugs 14 (56%) 12 (48%) 0.78
Using antidepressant drugs 12 (48%) 11 (44%) 1.00
Previous meditation/yoga experience 17 (68%) 10 (40%) 0.04
*Statistically significant difference
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Very high rates of study retention were achieved, with
45 (90%) participants completing outcome measures im-
mediately post-intervention, and 44 (88%) at follow-up,
3 months later. Missing values were generally low.
MBSR session attendance was only 60%, less than that
reported in other studies of MBIs for people with MS
(range 92–95%) [21, 24].
Regarding primary efficacy outcomes, large initial im-
provements were seen in perceived stress at post-
intervention in this study, but diminished to small at
three-month follow-up. Improvements in QOL were
very small at post-intervention and negligible at three-
month follow-up. For secondary outcomes, large im-
provements in depression, positive affect, anxiety, and
self-compassion were apparent immediately post-MBSR,
whilst at three-month follow-up large improvements
were present for mindfulness, positive affect, anxiety,
prospective memory, and self-compassion.
Comparison with existing literature
A large RCT testing MBSR in less disabled patients
with MS that took place in a university hospital loca-
tion reported a lower refusal rate (9%) than the
current study (24%), but they used an advertisement-
based ‘opt-in’ approach to recruitment, whereas the
current study employed a multifaceted strategy with a
greater potential to record refusal [24]. Outcome
measure completion in their study was 91% at six-
month follow-up, versus 88% in ours at 3 months
post MBSR. They also reported much higher session
attendance (92%) than the current study (60%),
perhaps reflecting lower levels of disability in their
participants (mean EDSS 3.0; SD 1.0 versus mean
EDSS 4.41; SD 1.75), or slightly higher level of mind-
fulness teacher experience (>9 years versus 7.5). They
delivered MBSR in smaller groups (n = 10–15 per
course), versus the relatively large group size in this
Fig. 2 Effect sizes with 95% confidence intervals immediately post-MBSR (adjusted for age/sex/SES/previous meditation/yoga): EQ5D – EuroQol
QOL measure adjusted for age/sex/SES/meditation/yoga. AUC – EuroQol area under the curve adjusted for age/sex/SES/meditation/yoga. PSS –
Perceived stress scale adjusted for age/sex/SES/meditation/yoga. MFIS – Modified fatigue impact scale adjusted for age/sex/SES/meditation/yoga.
MHI – Mental health inventory adjusted for age/sex/SES/meditation/yoga. PDQ – Perceived deficits questionnaire adjusted for age/sex/SES/medi-
tation/yoga. MSSS – Modified social support survey adjusted for age/sex/SES/meditation/yoga. PES – Pain effects scale adjusted for age/sex/SES/
meditation/yoga. IVIS – Impact of visual impairment scale adjusted for age/sex/SES/meditation/yoga. BCS – Bladder control scale adjusted for
age/sex/SES/meditation/yoga. BWCS – Bowel control scale adjusted for age/sex/SES/meditation/yoga. SSS – Sexual satisfaction scale adjusted for
age/sex/SES/meditation/yoga. MAAS – Mindful attention awareness scale adjusted for age/sex/SES/meditation/yoga. SCS-sf – Self-compassion
scale – short form adjusted for age/sex/SES/meditation/yoga. ELQ – Emotional lability questionnaire adjusted for age/sex/SES/meditation/yoga
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current study (n = 25). Average home-practice times
in their study (29.2 min) were comparable to those in
this current study (32.5 min).
No previous research studies have demonstrated
improvements in cognitive function among MS
patients following mindfulness training. With respect
to mental health outcomes, a high quality powered
RCT tested MBSR in people with MS, but did not
control for potential confounders in their analyses
[24]. The authors similarly reported improvements in
mental health, with smaller beneficial effects on
depression post-intervention (ES 0.65; p < 0.001),
which diminished less than ours at six-month follow-
up (ES 0.36; p < 0.05). They also found smaller im-
provements than us in anxiety post-intervention (ES
0.39; p < 0.001) and at six-month follow up (ES 0.36;
p < 0.05). The authors also reported that beneficial
effects on both anxiety and depression were greater
when subgroup analyses focused only on those with
pre-intervention scores deemed to be of clinical sig-
nificance [24].
More recently, an unpowered pilot study testing a tai-
lored remote Skype-delivered MBCT course minus
mindful-movement in people with progressive MS dem-
onstrated preliminary evidence to suggest likely effect-
iveness at improving mental health. Bogosian et al. [21]
included only those with levels of distress on the
General Health Questionnaire (GHQ) indicative of
psychiatric ‘case-ness’. Improvements with a large effect
size were noted in distress 3 months post MBCT (ES
0.97; p < 0.05); but were smaller for anxiety post inter-
vention (ES 0.40; p = 0.10), increasing to large 3 months
later (ES 0.86; p < 0.05). Improvements in depression
were smaller post-intervention (ES 0.65; p < 0.05), but
sustained 3 months later (ES 0.53; p < 0.05); whilst
improvements in MS symptom psychological impact
post-intervention were large (ES 0.99; p < 0.001) and
sustained 3 months later (ES 1.12; p < 0.01).
Fig. 3 Effect sizes with 95% confidence intervals 3 months post-MBSR (adjusted for age/sex/SES/previous meditation/yoga): EQ5D – EuroQol QOL
measure adjusted for age/sex/SES/meditation/yoga. AUC – EuroQol area under the curve adjusted for age/sex/SES/meditation/yoga. PSS – Per-
ceived stress scale adjusted for age/sex/SES/meditation/yoga. MFIS – Modified fatigue impact scale adjusted for age/sex/SES/meditation/yoga.
MHI – Mental health inventory adjusted for age/sex/SES/meditation/yoga. PDQ – Perceived deficits questionnaire adjusted for age/sex/SES/medi-
tation/yoga. MSSS – Modified social support survey adjusted for age/sex/SES/meditation/yoga. PES – Pain effects scale adjusted for age/sex/SES/
meditation/yoga. IVIS – Impact of visual impairment scale adjusted for age/sex/SES/meditation/yoga. BCS – Bladder control scale adjusted for
age/sex/SES/meditation/yoga. BWCS – Bowel control scale adjusted for age/sex/SES/meditation/yoga. SSS – Sexual satisfaction scale adjusted for
age/sex/SES/meditation/yoga. MAAS – Mindful attention awareness scale adjusted for age/sex/SES/meditation/yoga. SCS-sf – Self-compassion
scale – short form adjusted for age/sex/SES/meditation/yoga. ELQ – Emotional lability questionnaire adjusted for age/sex/SES/meditation/yoga
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Four other small studies have reported similar bene-
fits in anxiety [25, 26], depression [23, 25, 26], pain
[27], balance [23, 26], and QOL [23], but methodo-
logical limitations such as small sample size [26],
failure to randomise [23, 27], failure to control for re-
searcher bias [23], and selective outcome reporting
[26] limit their relevance. Furthermore, modifications
to their intervention approaches, such as substituting
Tai Chi in place of Hatha Yoga [23, 26, 27], or not
taking place in a group format [26] raise questions
regarding the relevance of their findings to the
current study. Nevertheless, taking the findings from
the current study into account, there is now a grow-
ing body of evidence to suggest likely effectiveness of
MBIs for treating anxiety in MS. The interim benefits
reported on depression following MBSR in this study
and one other high quality RCT [24] are also encour-
aging, but the decline in effect seen at study end-
points suggest that there may be scope for judicious
tailoring of MBSR to render beneficial treatment ef-
fects more stable. One such measure that has worked
in MBCT for depression is the provision of post-
completion ‘drop-in’ sessions, where beneficial effects
have persisted for up to 2 years [38].
We also measured mindfulness and self-compassion,
thought key components in how MBIs work [15, 16,
22]. No previous studies in people with MS have
assessed the impact of MBI training on levels of
mindfulness. Meta-analysis suggests that improve-
ments in mindfulness may mediate improved mental
health in non-MS populations [39]. Cross-sectional
analyses [40–42] (n = 69–119) support that increased
mindfulness is associated with greater positive affect,
improved relationship satisfaction, less anxiety, less
stress, improved wellbeing and QOL, and enhanced
coping in people with MS. Having more self-
compassion is associated with a greater resilience to
anxiety, depression and stress in other LTCs [43], and
may also make a small contribution to better mental
health in people with MS [22].
Strengths and limitations
We followed the MRC guidelines for developing and
evaluating complex interventions [13]. The small size
of the study is a limitation, but is acceptable in feasi-
bility work. The high proportion of female patients in
this study (92%) is notable when compared with pre-
vious research in this area (range 69–100% [23–27]).
This could reflect the higher incidence of stress-
related mental health comorbidities in women with
MS in Scotland [44], a greater stigma among men
towards reporting mental health concerns [45], or
that men may be less willing to participate in re-
search studies [46].
We adjusted for common confounding variables in
this study, along with those found to differ significantly
at baseline. As this study was not powered to detect sig-
nificant baseline differences, the findings from our ana-
lyses must thus be treated with caution (for example
other variables such as baseline between group differ-
ences in diagnoses of anxiety and depression, antidepres-
sant usage, disease activity and/or disease modifying
drug (DMD) therapy could conceivably also impact on
stress levels and effectiveness and should thus be consid-
ered in a future definitive study, powered to detect sig-
nificant differences on these variables).
Evidence of effectiveness cannot be reliably deter-
mined in a small, unpowered sample. In this scenario,
significance levels are unreliable, and observed benefi-
cial treatment effects on stress, mood, and cognition
can, at best, only be seen as an indication of likely
effectiveness in a future phase three trial. Further, the
novel findings of subjective improvements in cognitive
function could be better contextualised if combined
with a more objective neuropsychological assessment.
Criticisms of commonly used objective measures of
cognitive function are that they are either too short,
too long, too generic, fail to detect deficits, or require
to be administered by an expert [47]. The Brief Inter-
national Cognitive Assessment for Multiple Sclerosis
(BICAMS) is an internationally validated, standardised
assessment tool with good reliability and validity,
with the added advantage over other neuropsycho-
logical tests that it can be administered by a non-
expert and could thus be used in a definitive phase
three study [48].
The follow-up period post MBSR was relatively short
in this study i.e. 3 months, and a future phase three trial
could assess whether MBIs might have more lasting ef-
fects. Further optimisation work will help with the cre-
ation of a bespoke MBI for people with MS, which may
improve recruitment and render beneficial treatment ef-
fects more stable.
Conclusion
Delivering MBSR to people with MS in a NHS setting is
feasible. We achieved our recruitment target of 50
people within the specified time limits. Levels of reten-
tion i.e. completion rates for outcome measures were
good post-intervention, and at follow-up. Encouraging
improvements were noted on various outcome mea-
sures, in particular anxiety, with most measures having
acceptable levels of missing values. However, initial
beneficial effects on stress and depression were greatly
diminished at study endpoint and only 60% of partici-
pants completed MBSR, suggesting that further opti-
misation is required before proceeding to a phase-3
definitive trial.
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